The Esthetic Clinics and QR678 Research collaborate on groundbreaking research mapping hair growth pathways, potentially ...

Sarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments ...

One of North Carolina's largest biotechnology companies is expanding its operations with a $2 billion investment.

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

Drugmaker Sarepta Therapeutics said late Friday it won't comply with a request from the Food and Drug Administration to halt ...

Investing.com -- Sarepta Therapeutics Inc (NASDAQ: SRPT) stock tumbled 10% following the announcement that the U.S. Food and Drug Administration has placed a clinical hold on the company’s ...

Presentation to highlight how Senti Bio's novel first-in-class logic-gated CAR-NK cell therapy kills leukemic cells while protecting healthy bone marrow ...

Sarepta stock has tanked. Most investors don’t see the drugmaker’s executive management as credible following the failure to disclose a patient death, a BMO survey suggests.

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...